Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Merz Pharma GmbH & Co. Kgaa maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company is currently managing 7 pending office actions. This number of pending actions suggests a broad and active prosecution strategy within the pharmaceutical sector. The volume of activity indicates that the company is frequently interacting with the patent office to secure its intellectual property rights.
The prosecution work for this portfolio is distributed across 7 distinct examiners and 6 distinct art units. This wide distribution shows that the company's patent applications cover a variety of technical sub-fields within the Biotechnology & Pharmaceuticals area. Managing multiple examiners requires a versatile approach to prosecution, as each individual may have different interpretations of patent law and office procedures. The involvement of 6 art units further highlights the technical diversity of the portfolio.
CHHAY, BONIRATH is identified as the busiest examiner for Merz Pharma GmbH & Co. Kgaa. This examiner is responsible for 1 pending office action. Although CHHAY, BONIRATH is the busiest examiner, the decentralized nature of the company's prosecution is evident. With each of the 7 pending office actions likely being handled by a different person, the company must coordinate across many different examination styles.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §103 only | 1 (14%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHHAY, BONIRATH | 1 | 62.5% | +0.0% |
| BOATENG, AFUA BAMFOAA | 1 | 46.7% | +64.5% |
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| PONTON, JAMES D | 1 | 80.0% | +32.1% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
| PRICE, NATHAN R | 1 | 53.4% | +38.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18620513 | COMPOSITION COMPRISING BOTULINUM TOXIN | FAN, LYNN Y | 34d |
| 18841985 | USE OF BOTULINUM TOXIN FOR REDUCTION OF SKIN PORE SIZE AND SEBUM PRODUCTION | CHHAY, BONIRATH | — |
| 18838546 | LIQUID BOTULINUM TOXIN FORMULATION AND USE THEREOF | BOATENG, AFUA BAMFOAA | — |
| 18292312 | SYRINGE BARREL WITH VARYING SILICONE LAYER THICKNESSES, SYRINGE COMPRISING SAME AND USES THEREOF | PONTON, JAMES D | — |
| 18573732 | CROSS-LINKING POLYSACCHARIDE WITH FIBROIN AND USES OF THE OBTAINED MATERIAL | ALDARONDO, DASIA ALI | — |
| 18043663 | PLUNGER AND FINGER GRIP FOR A SYRINGE ASSEMBLY, METHOD FOR MAKING THEM, SYRINGE ASSEMBLY, KIT AND USE OF THE SAME | PRICE, NATHAN R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18620513 | COMPOSITION COMPRISING BOTULINUM TOXIN | FAN, LYNN Y | 34d |
| 18838546 | LIQUID BOTULINUM TOXIN FORMULATION AND USE THEREOF | BOATENG, AFUA BAMFOAA | — |
| 18292312 | SYRINGE BARREL WITH VARYING SILICONE LAYER THICKNESSES, SYRINGE COMPRISING SAME AND USES THEREOF | PONTON, JAMES D | — |
| 18178041 | COMPOSITION FOR IMPROVING THE APPEARANCE OF AGEING SKIN | PURDY, KYLE A | — |
| 18043663 | PLUNGER AND FINGER GRIP FOR A SYRINGE ASSEMBLY, METHOD FOR MAKING THEM, SYRINGE ASSEMBLY, KIT AND USE OF THE SAME | PRICE, NATHAN R | — |
| Art Unit | Apps |
|---|---|
| 3783 | 2 |
| 1645 | 1 |
| 1617 | 1 |
| 1759 | 1 |
| 1647 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18841985 | USE OF BOTULINUM TOXIN FOR REDUCTION OF SKIN PORE SIZE AND SEBUM PRODUCTION | CHHAY, BONIRATH | 1645 | §103§112 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18838546 | LIQUID BOTULINUM TOXIN FORMULATION AND USE THEREOF | BOATENG, AFUA BAMFOAA | 1617 | §102§103§112 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18620513 | COMPOSITION COMPRISING BOTULINUM TOXIN | FAN, LYNN Y | 1759 | §101§103§112DP | Final Rejection | 34d | Pending | Mar 28, 2024 |
| 18292312 | SYRINGE BARREL WITH VARYING SILICONE LAYER THICKNESSES, SYRINGE COMPRISING SAME AND USES THEREOF | PONTON, JAMES D | 3783 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18573732 | CROSS-LINKING POLYSACCHARIDE WITH FIBROIN AND USES OF THE OBTAINED MATERIAL | ALDARONDO, DASIA ALI | 1647 | §102§103 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18178041 | COMPOSITION FOR IMPROVING THE APPEARANCE OF AGEING SKIN | PURDY, KYLE A | 1611 | §103 | Non-Final OA | — | Pending | Mar 03, 2023 |
| 18043663 | PLUNGER AND FINGER GRIP FOR A SYRINGE ASSEMBLY, METHOD FOR MAKING THEM, SYRINGE ASSEMBLY, KIT AND USE OF THE SAME | PRICE, NATHAN R | 3783 | §102§103§112 | Final Rejection | — | Pending | Mar 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMerz Pharma GmbH & Co. Kgaa has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Bonirath Chhay has the most, with 1 of Merz Pharma GmbH & Co. Kgaa's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
